RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced
FDA approved blinded, multi-centric Phase-3 trial (NCTsrc6489src28) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU...Read More
FDA approved blinded, multi-centric Phase-3 trial (NCTsrc6489src28) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU...Read More
Blood cancer death rates have dipped in recent decades, dramatically boosting 5-year survival rates in leukemia, lymphoma, and myeloma. Still,...